Erasca Vows to Fight Revolution Medicines Patent Allegations – Stifel Stays Bullish
Erasca denies patent claims by Revolution Medicines, will fight back; Stifel keeps Buy rating.
/ 1659 items
#XY↓
PFS Triumph or OS Flop? Why CMPX Shares Plunged Despite Positive Cancer Results
Compass Therapeutics fell after cancer drug improved outcomes but failed to show clear survival benefit due to patient crossover.
Veradermics’ Oral Hair Loss Pill Scores Major Win in Late-Stage Trial
Veradermics’ hair pill VDPHL01 showed strong results, growing 30+ hairs/cm in trials, safe, and may become a new baldness treatment.
Oruka’s Long-Acting Psoriasis Drug Hits 63.5% Complete Skin Clearance in Mid-Stage Trial
Oruka’s new psoriasis drug cleared skin in most patients with few side effects and may need only yearly injections.
Eli Lilly Acquires Ajax Therapeutics to Advance New Treatment for Rare Blood Cancers
Eli Lilly buys Ajax to develop a new pill for rare blood cancers that may work longer and better than current treatments.
Ligand Buys Xoma for $740M, Doubling Its Drug Royalty Portfolio
Ligand buys Xoma for $740M cash, boosting its drug royalty portfolio to 200+ medicines and spreading investment risk.